About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
2019
04
Mar 2020
16:05 E.S.T.
Cellectis and Servier Execute the Amendment Confirming the Expansion of their Collaboration on UCART19 Products
Read more
25
Feb 2020
16:30 E.S.T.
Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST
Read more
18
Feb 2020
16:30 E.S.T.
Cellectis and Servier Expand Collaboration on UCART19 Products
Read more
15
Jan 2020
16:30 E.S.T.
First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia
Read more
12
Jan 2020
16:00 E.S.T.
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
Read more
06
Jan 2020
16:30 E.S.T.
An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery
Read more
Prev
3
4
5